Physician profile
J Michael Elser
NPI 1982677894
$3,639.18
in general payments reported to CMS, 2019-2025
29 companies · $176 in 2025
The $176 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,187 · 2020: $795 · 2021: $812 · 2022: $293 · 2023: $218 · 2024: $159 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $437 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $436.71 |
| Education | $115.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $424.54 | 2019-2024 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $411.96 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $338.05 | 2019-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Novo Nordisk INC | $322.50 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $303.99 | 2019-2024 | Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $279.44 | 2019-2023 | Breztri |
| Janssen Pharmaceuticals, INC | $198.30 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $167.00 | 2019-2021 | |
| Allergan, INC. | $154.88 | 2019-2020 | |
| Abbvie INC. | $124.10 | 2020-2024 | |
| Eisai INC. | $121.97 | 2020-2022 | |
| Amgen INC. | $117.35 | 2019-2021 | |
| Pfizer INC. | $82.61 | 2019-2022 | |
| Amarin Pharma, INC. | $76.50 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $73.04 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $62.97 | 2022 | |
| Vanda Pharmaceuticals INC. | $61.00 | 2021-2025 | Fanapt |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.98 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $32.82 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $30.64 | 2020-2021 | |
| Vertex Pharmaceuticals Incorporated | $30.47 | 2025 | |
| Astellas Pharma US INC | $29.49 | 2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $29.25 | 2021 | |
| Exact Sciences Corporation | $25.24 | 2025 | The Cologuard Plus Collection Kit |
| Intra-Sana Laboratories | $19.98 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Dexcom, INC. | $19.52 | 2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $17.04 | 2022 | |
| Sanofi Pasteur INC. | $15.76 | 2019 | |
| Qiagen, LLC | $12.79 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw J Elser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.